Corteva (CTVA) CTVA Q4 Financial Results Summary
QuoteReporter
Corteva, Inc. (CTVA) Q4 2025 Financial Results Summary
On February 3, 2026, Corteva, Inc. (NYSE: CTVA) reported its financial results for the fourth quarter and the full year ended December 31, 2025.
Q4 2025 Results Overview
- Net Sales: $3.91 billion
- Decreased 2% compared to Q4 2024
- Loss from Continuing Operations (After Tax): $(537) million
- Compared to a loss of $(50) million in Q4 2024
- GAAP Earnings Per Share (EPS): $(0.80) (Not meaningful for comparison)
- Organic Sales: $3.82 billion
- Decreased 4% from Q4 2024
- Operating EBITDA: $446 million
- Decreased 15% from Q4 2024
- Operating EPS: $0.22
- Decreased 31% from Q4 2024
FY 2025 Results Overview
- Net Sales: $17.40 billion
- Increased 3% compared to FY 2024
- Income from Continuing Operations (After Tax): $1.20 billion
- Increase of 40% from FY 2024
- GAAP EPS: $1.75
- Increased 43% compared to FY 2024
- Organic Sales: $17.56 billion
- Increased 4% from FY 2024
- Operating EBITDA: $3.85 billion
- Increased 14% from FY 2024
- Operating EPS: $3.34
- Increased 30% from FY 2024
- Free Cash Flow: $2.9 billion
- Increased 69% from FY 2024
Key Highlights for Full Year 2025
- Seed Segment:
- Net Sales: $9.90 billion, increased 4% vs. FY 2024
- Operating EBITDA: $2.64 billion, up 19% from FY 2024
-
Volume increase of 2%, price/mix increase of 3%
-
Crop Protection Segment:
- Net Sales: $7.50 billion, increased 2% vs. FY 2024
- Operating EBITDA: $1.35 billion, increased 6% from FY 2024
-
Volume increase of 5%, price decline of 2%
-
Cash Returns to Shareholders: Total cash returned exceeded $1.5 billion.
Q4 2025 Segment Summary
Seed
- Net Sales: $1.74 billion
- Decreased 2% from Q4 2024
- Volume decreased 8%; partially offset by a 3% increase in price/mix.
- Operating EBITDA: $124 million
- Increased 33% from Q4 2024
Crop Protection
- Net Sales: $2.17 billion
- Decreased 1% from Q4 2024
- Volume decreased 2%, price decline of 1%; partly offset by foreign currency gains.
- Operating EBITDA: $360 million
- Decreased 22% from Q4 2024
2026 Guidance
- Operating EBITDA: Expected to be between $4.0 billion and $4.2 billion, reflecting 7% growth at mid-point.
- Operating EPS: Expected to be between $3.45 and $3.70 per share, reflecting 7% growth at mid-point.
Corporate Actions & Dividend Information
- Corteva has not declared a quarterly dividend as per the latest report.
- A significant resolution with Bayer has enhanced the company’s operational flexibility and is expected to assist in achieving a net royalty income position of $1 billion by 2035.
Conclusion
Corteva’s performance in Q4 2025 reflects a challenging environment, resulting in some declines in net sales and operating metrics. However, the company indicated strong overall annual growth and positive guidance for 2026, alongside strategic actions that may enhance future profitability.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts in millions)
| 4Q 2025 | 4Q 2024 | % Change | Organic1 % Change | |
|---|---|---|---|---|
| Net Sales | $3,910 | $3,978 | (2)% | (4)% |
| North America | $1,478 | $1,563 | (5)% | (5)% |
| EMEA | $424 | $448 | (5)% | (9)% |
| Latin America | $1,653 | $1,622 | 2% | (3)% |
| Asia Pacific | $355 | $345 | 3% | 7% |
| Net Sales | $17,401 | $16,908 | 3% | 4% |
| North America | $9,024 | $8,660 | 4% | 5% |
| EMEA | $3,110 | $3,124 | – | 2% |
| Latin America | $3,928 | $3,776 | 4% | 4% |
| Asia Pacific | $1,339 | $1,348 | (1)% | 2% |
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in millions)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Current Assets | $X,XXX | $X,XXX |
| Total Assets | $X,XXX | $X,XXX |
| Current Liabilities | $X,XXX | $X,XXX |
| Long-term Liabilities | $X,XXX | $X,XXX |
| Total Liabilities | $X,XXX | $X,XXX |
| Stockholders’ Equity | $X,XXX | $X,XXX |
| Total Liabilities and Equity | $X,XXX | $X,XXX |
(Note: Replace X,XXX with the actual figures from the original table provided in the press release, which appears to be missing from the provided text.)